Inet Technologies Reported Earnings

Inet Technologies (INTI) reported breakeven results on revenue of $0.00 million for the . .

Inhibitor Therapeutics Inc. is a pharmaceutical development company. It discovers, develops and plans to commercialize therapeutics for cancerous and non-cancerous proliferation disorders. The company's lead product consists of SUBA-Itraconazole, a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for treatment of prostate and lung cancers, which are in clinical stage. Inhibitor Therapeutics Inc., formerly known as HedgePath Pharmaceuticals Inc., is based in Tampa, United States.